Pharmacokinetic Structure Modification
Pharmacokinetic Structure Modification - Related Videos
10:02
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
0 Views •
Cited by 59 •
2016
Rabbits are widely used to study the pharmacokinetics of intraocular drugs. We describe a method for conducting pharmacokinetic studies of intraocular drugs using rabbit eyes.
02:25
Spreading of Chromatin Modifications
0 Views •
2020
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex. Writers The writer is an enzyme that can...
02:32
Histone Modification
0 Views •
2020
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression. Acetylation The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
07:08
Detection of Histone Modifications in Plant Leaves
0 Views •
Cited by 22 •
2011
A reliable and useful approach to detect histone modifications on specific plant genes is described. The approach combines chromatin immunoprecipitation (ChIP) and real-time quantitative PCR. It allows detection of histone modifications on specific genes with a role in diverse physiological processes.
01:10
Pharmacokinetics: Overview
0 Views •
2023
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...
FAQs
These molecular properties influence whether a drug dissolves, crosses biological environments, and remains available for absorption. Adjusting functional groups or substituents can change the balance among lipophilicity, ionization, and solubility rather than improving one property in isolation. The resulting profile can support more effective absorption and help shape the drug’s distribution and overall exposure.
Functional groups and substituents can alter how a molecule interacts with drug-metabolizing enzymes and transport proteins. Those interactions may change the rate at which the compound is metabolized, transported, or cleared. Increasing metabolic stability may help maintain exposure for longer, whereas reducing stability can help limit persistence, unwanted accumulation, or prolonged effects when those outcomes are clinically undesirable.
Structural changes can shift the balance between persistence and clearance, producing a longer or shorter half-life. A longer half-life may support sustained exposure and less frequent dosing, while a shorter half-life may help prevent excessive accumulation. The preferred direction depends on the intended therapeutic profile, including how long the drug should remain active and how predictable its exposure must be.
A development workflow starts by identifying the desired pharmacokinetic profile, such as improved oral bioavailability, altered tissue exposure, or a specific half-life. Researchers then adjust functional groups, substituents, or related molecular properties and examine how those changes affect absorption, distribution, metabolism, and excretion. Linking each structural change to its resulting behavior guides selection of more suitable candidates.
Researchers may pursue these modifications when a candidate is not absorbed efficiently by mouth or does not reach the desired tissues at useful levels. Changes that improve relevant molecular properties can increase oral bioavailability or enhance tissue exposure. These goals connect chemical optimization with therapeutic performance, helping development teams prioritize compounds that may achieve effective concentrations with practical dosing.
Pharmacokinetic structure modification can produce compounds with more predictable exposure, extended or shortened half-lives, and reduced unwanted accumulation. Those outcomes are relevant to selecting dosing schedules and anticipating whether drug levels may persist excessively. In clinical development, the structure-behavior relationship therefore helps connect molecular design with efficacy, safety, and the practical management of treatment.